Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Jul;26(1):94–96. doi: 10.1128/aac.26.1.94

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

J D Gay, D R DeYoung, G D Roberts
PMCID: PMC179925  PMID: 6236748

Abstract

The activities of ciprofloxacin and norfloxacin against 100 mycobacteria isolates were studied in vitro by the 1% standard proportion method. Ciprofloxacin was more active against M. tuberculosis and M. fortuitum with MICs of 1.0 and 0.25 microgram/ml, respectively, against 90% of isolates; norfloxacin had MICs of 8.0 and 2.0 micrograms/ml, respectively, against 90% of isolates.

Full text

PDF
94

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauernfeind A., Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983 Apr;2(2):111–115. doi: 10.1007/BF02001575. [DOI] [PubMed] [Google Scholar]
  2. Cynamon M. H., Patapow A. In vitro susceptibility of Mycobacterium fortuitum to cefoxitin. Antimicrob Agents Chemother. 1981 Jan;19(1):205–207. doi: 10.1128/aac.19.1.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dalovisio J. R., Pankey G. A. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin. J Infect Dis. 1978 Mar;137(3):318–321. doi: 10.1093/infdis/137.3.318. [DOI] [PubMed] [Google Scholar]
  4. Dutt A. K., Stead W. W. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med. 1979 Sep;67(3):449–453. doi: 10.1016/0002-9343(79)90792-7. [DOI] [PubMed] [Google Scholar]
  5. Eandi M., Viano I., Di Nola F., Leone L., Genazzani E. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. Eur J Clin Microbiol. 1983 Jun;2(3):253–259. doi: 10.1007/BF02029528. [DOI] [PubMed] [Google Scholar]
  6. Gadebusch H. H., Shungu D. L., Weinberg E., Chung S. K. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents. Infection. 1982 Jan;10(1):41–44. doi: 10.1007/BF01640837. [DOI] [PubMed] [Google Scholar]
  7. Haase D., Urias B., Harding G., Ronald A. Comparative in vitro activity of norfloxacin against urinary tract pathogens. Eur J Clin Microbiol. 1983 Jun;2(3):235–241. doi: 10.1007/BF02029524. [DOI] [PubMed] [Google Scholar]
  8. Khan M. Y., Gruninger R. P., Nelson S. M., Klicker R. E. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. Antimicrob Agents Chemother. 1982 May;21(5):848–851. doi: 10.1128/aac.21.5.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Khan M. Y., Siddiqui Y., Gruninger R. P. Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1981 Aug;20(2):265–266. doi: 10.1128/aac.20.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. King A., Warren C., Shannon K., Phillips I. In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother. 1982 Apr;21(4):604–607. doi: 10.1128/aac.21.4.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Newsom S. W., Matthews J., Amphlett M., Warren R. E. Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids. J Antimicrob Chemother. 1982 Jul;10(1):25–30. doi: 10.1093/jac/10.1.25. [DOI] [PubMed] [Google Scholar]
  12. Rosenzweig D. Y. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest. 1979 Feb;75(2):115–119. doi: 10.1378/chest.75.2.115. [DOI] [PubMed] [Google Scholar]
  13. Swenson J. M., Thornsberry C., Silcox V. A. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob Agents Chemother. 1982 Aug;22(2):186–192. doi: 10.1128/aac.22.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tisdall P. A., Roberts G. D., Anhalt J. P. Identification of clinical isolates of mycobacteria with gas-liquid chromatography alone. J Clin Microbiol. 1979 Oct;10(4):506–514. doi: 10.1128/jcm.10.4.506-514.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wallace R. J., Jr, Dalovisio J. R., Pankey G. A. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents. Antimicrob Agents Chemother. 1979 Nov;16(5):611–614. doi: 10.1128/aac.16.5.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wallace R. J., Jr, Jones D. B., Wiss K. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis. 1981 Sep-Oct;3(5):898–904. doi: 10.1093/clinids/3.5.898. [DOI] [PubMed] [Google Scholar]
  17. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979 Jan;119(1):107–159. doi: 10.1164/arrd.1979.119.1.107. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES